- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model ...
Lead asset INZ-701, a novel enzyme replacement therapy or ERT, is in a phase 2 trial targeting ENPP1 Deficiency. It has a Rare Pediatric Disease Designation in the US, a fast track designation, and an ...
Calciphylaxis development has been linked to lower levels of plasma pyrophosphate (PPi), and INZ-701 can significantly increase PPi levels in patients on hemodialysis, phase 1 data show. A phase 1 ...
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback